Key Highlights
- India’s Sun Pharmaceutical Industries has allegedly put forward a $13 billion all-cash acquisition proposal for Organon (OGN)
- If finalized, this transaction would represent Sun Pharma’s biggest acquisition in company history, backed by financing from JP Morgan, MUFG, and Citi
- Shares of OGN surged approximately 25% during Friday trading, building on a 20% year-to-date increase
- German pharmaceutical firm Grünenthal and private equity group EQT have reportedly submitted rival proposals
- Sun Pharma’s latest bid increases its earlier $12 billion proposal from earlier in the month
Shares of Organon (OGN) experienced a dramatic surge exceeding 25% on Friday following reports that India’s Sun Pharmaceutical Industries has put together a $13 billion all-cash acquisition proposal for the women’s health-focused pharmaceutical company.
The Economic Times broke the story Thursday evening, referencing sources with knowledge of the discussions. OGN climbed approximately 8% during afterhours trading before building on those gains throughout Friday’s regular session.
When the initial reports surfaced, Organon carried a market capitalization of merely $2.2 billion. A $13 billion acquisition proposal would signify an extraordinary premium relative to the stock’s recent trading levels.
Should the transaction close, it would become Sun Pharma’s most significant acquisition in its corporate history. The all-cash structure is reportedly backed by complete financing commitments from JP Morgan, MUFG, and Citi.
Sun Pharma intends to integrate Organon directly into its current business structure. The proposal does not involve issuing Sun Pharmaceutical equity to existing Organon shareholders.
This marks Sun Pharma’s second approach toward acquiring the company. Reports from earlier this month indicated the Indian pharmaceutical giant submitted a $12 billion proposal. Friday’s reported $13 billion offer represents a $1 billion escalation within just weeks.
Competitive Acquisition Landscape
Sun Pharma faces competition in its pursuit of Organon. Germany’s Grünenthal pharmaceutical company and Sweden-based private equity firm EQT have both reportedly submitted competing acquisition proposals.
The competitive interest underscores the attractiveness of Organon’s product portfolio — an extensive collection of medications and therapies primarily centered on women’s healthcare, complemented by its domestic manufacturing capabilities in the United States.
Organon became an independent entity through a spinoff from Merck in June 2021. The stock has experienced volatility since then, trading down roughly 30% over the trailing twelve months despite Friday’s substantial rally.
Extraordinary Trading Activity
News of the potential acquisition sparked intense buying interest. Approximately 5.2 million OGN shares traded hands shortly after Friday’s opening bell — nearly equaling the stock’s complete three-month average daily volume of 5.9 million shares within just the initial trading hours.
Friday’s 25.47% rally elevated the stock’s year-to-date performance to a positive 20.25% return.
OGN was changing hands above $9.20 per share during Thursday’s afterhours session, representing a significant increase from its relatively depressed $2.2 billion market capitalization at Thursday’s regular session close.
Neither Sun Pharma nor Organon has issued official confirmation regarding any acquisition agreement as of Friday afternoon.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
